Novartis

Companies Novartis

News Novartis

• Oxford BioMedica Announces Lentiviral Vector Development and Manufacturing Collaboration

  Oxford BioMedica plc announced that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector® gene delivery technology.  Under the terms of the agreement, Oxford BioMedica will also provide certain process development services and expec more

• European Medicines Agency supports Members States in coordinating action regarding seasonal influenza vaccines produced by Novartis

  A number of European Union (EU) Member States have halted the use, as a precautionary measure, of some anti-influenza vaccines manufactured by Novartis Vaccines, because of a suspected quality defect.  The Italian Medicines Agency (AIFA) was first informed of the suspected quality defect by the manu more

• Evotec receives Milestone in Drug Discovery Collaboration

  Evotec AG announced that it has received a pre-clinical milestone from its Drug Discovery Collaboration with Novartis. No financial details were given. Under the terms of the agreement, Evotec is responsible for progressing the program up to pre-clinical development and Novartis will then have the r more

White papers Novartis

• Orphan Drugs – An Alternative to the declining Blockbuster Model?
  

  Up until the new millennium, the pharmaceutical industry grew stronger by 11%. However, the blockbuster model is increasingly at risk and the declining growth rates in the industry require a search for new strategies. In this context, orphan drugs are becoming increasingly important more

Publications Novartis

• Fingolimod for the treatment of relapsing multiple sclerosis

  Fingolimod 0.5 mg (Gilenya™, Novartis Pharmaceuticals Corporation, FL, USA) is the first once-daily oral therapy approved for relapsing forms of multiple sclerosis (MS) in the USA and for rapidly evolving severe MS or highly active disease despite IFN-β treatment in Europe. An extensive clinical dev more

• Mitoxantrone Targets the ATP-binding Site of FAK, Binds the FAK Kinase Domain and Decreases FAK, Pyk-2, c-Src, and IGF-1R In Vitro Kinase Activities

  Abstract: Focal Adhesion Kinase (FAK) is a non-receptor kinase that is overexpressed in many types of tumors and plays a key role in cell adhesion, spreading, motility, proliferation, invasion, angiogenesis, and survival. Recently, FAK has been proposed as a target for cancer therapy, and we more

• Automatic analysis of the micronucleus test in primary human lymphocytes using image analysis

  The in vitro micronucleus test (MNT) is a well-established test for early screening of new chemical entities in industrial toxicology. For assessing the clastogenic or aneugenic potential of a test compound, micronucleus induction in cells has been shown repeatedly to be a sensitive and a specific more

Market studies Novartis

• China Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: 2012 is a very important year for the country as the government look to carry on their achievements following the healthcare reform in 2009. We highlight that the expansion of the National Essential Drug List (NEDL) slated to happen this year will bring strong opportunities for pharmaceuti more

• Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report provides comp more

• Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Osteopenia Therapeutics market. The report identifies the more

Websites Novartis